Federal judge upholds Cabometyx patent in Exelixis' generic battle
A federal judge upheld a key patent on Exelixis’ cancer drug Cabometyx on Thursday, dealing a blow to MSN Laboratories’ potential generic version.
Exelixis filed suit against MSN back in 2019, after the latter company submitted an abbreviated new drug application (ANDA) for its Cabometyx generic. If MSN’s drug wins approval, Exelixis argued in the initial complaint that it would infringe on at least one or two claims of a patent dubbed ‘776, which expires in 2030, according to the FDA’s Orange Book.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.